Announced yesterday, the deal will expand Seres’ manufacturing capabilities for SER-109, an oral microbiome therapeutic containing Firmicutes spores, which normally live in the healthy microbiome.
SER-109 is designed to prevent rCDI by modulating the disrupted microbiome to resist C. difficile colonisation and growth.
Further terms will see Bacthera, a Basel-based contract development and manufacturing firm, provide drug substance manufacturing and filling of the final product formulation into Lonza’s Capsugel hypromellose plant-based capsule range.
“This collaboration truly exemplifies Bacthera's leading offering for LBP manufacturing as a strategic partner on the path to commercialsation,” explains Jean-Christophe Hyvert, President, Biologics and Cell and Gene, Lonza.
“Bacthera will utilise a facility inspired by the Ibex Solutions to offer an assured supply, enabling its customers to mark a significant milestone in the advance of microbiome-targeting therapies."
Hyvert, who joined Lonza in 2017, is referring to the new LBP Manufacturing facility located at Lonza's site in Visp, Switzerland.
The 12’000 m2 Microbiome Center of Excellence covers three manufacturing floors, including capacity for commercial production. One of the floors will be dedicated to the manufacturing of SER-109.
“We are proud to be part of bringing an entirely new class of medicines to people who have a profound need for it,” adds Lukas Schüpbach, CEO, Bacthera.
“With our new Microbiome Center of Excellence in Visp, we are looking forward to supporting the manufacturing of potentially life-saving microbiome-based treatments, such as SER-109."
"enter" - Google News
November 12, 2021 at 05:25PM
https://ift.tt/3HgBZOV
Bacthera and Seres enter deal to manufacture gut infection-tackling biotherapeutic - NutraIngredients.com
"enter" - Google News
https://ift.tt/2TwxTMf
https://ift.tt/3d6LMHD
Bagikan Berita Ini
0 Response to "Bacthera and Seres enter deal to manufacture gut infection-tackling biotherapeutic - NutraIngredients.com"
Post a Comment